Ketamine and Esketamine for Treatment-Resistant Depression: Evidence, Gaps, and Clinical Implications (2026 Review)
A 2026 narrative review examines the rapid antidepressant effects, durability, safety, and comparative efficacy of ketamine and esketamine in treatment-resistant depression, highlighting regional data gaps and practical management insights.
Evidence for Ketamine and Esketamine in Treatment-Resistant Depression
Ketamine and esketamine demonstrate rapid antidepressant effects in treatment-resistant depression, but the magnitude and durability of these effects remain uncertain due to limited controlled data. Treatment-resistant depression (TRD), typically defined as inadequate response to at least two antidepressants, affects a significant proportion of patients and imposes substantial health and economic burdens globally. Intravenous racemic ketamine and intranasal esketamine, both non-monoaminergic agents, have emerged as alternatives to traditional therapies, offering rapid symptom relief that distinguishes them from standard antidepressants.
Randomized controlled trials (RCTs) indicate that both agents can induce clinically meaningful improvements within hours to days. However, indirect comparisons suggest that racemic ketamine may produce larger antidepressant effects than esketamine, though not always reaching statistical significance. Notably, two of three short-term phase 3 trials of esketamine—each combining esketamine with a newly initiated oral antidepressant—failed to meet their primary endpoints, underscoring the variability in response and the need for more robust head-to-head data.
Mechanisms, Durability, and Comparison with Other Therapies
Ketamine and esketamine act primarily as N-methyl-D-aspartate (NMDA) receptor antagonists, modulating glutamatergic neurotransmission and promoting synaptic plasticity, which may underlie their rapid antidepressant effects. The durability of these effects, however, is less well established. For esketamine, the most robust evidence comes from a single randomized withdrawal trial in responders, while maintenance data for intravenous ketamine are limited to open-label studies lacking control groups.
Comparative studies position ketamine as non-inferior to electroconvulsive therapy (ECT) in a large open-label trial among non-psychotic patients referred for ECT, but inferior in a separate trial involving hospitalized patients. Esketamine outperformed extended-release quetiapine in an open-label trial, suggesting potential utility as an augmentation strategy. These findings highlight the importance of patient selection, clinical context, and comparative effectiveness when considering rapid-acting interventions for TRD.
Safety Profile and Practical Management
The safety profile of ketamine and esketamine is generally manageable, with acute adverse effects including transient dissociation, elevated blood pressure, and sedation. While concerns about bladder toxicity and misuse persist, current evidence does not convincingly demonstrate significant risk of bladder injury at therapeutic doses, and reports of misuse vary across sources. Practical management approaches emphasize patient monitoring during and after administration, blood pressure checks, and careful consideration of comorbidities.
Importantly, the review identifies substantial regional data gaps, particularly in the Gulf states and Saudi Arabia, where only a small uncontrolled series of twenty patients was identified. This lack of controlled outcome data complicates efforts to develop regionally tailored protocols and underscores the need for local research investment.
Risks, Unknowns, and Decision Criteria
Key risks and unknowns in the clinical use of ketamine and esketamine include the uncertain durability of response, optimal dosing and maintenance schedules, and the potential for misuse or diversion. The limited availability of long-term, controlled data—especially for maintenance intravenous ketamine—poses challenges for clinicians seeking to balance rapid symptom relief against the risks of repeated exposure.
A non-obvious implication highlighted by the review is the potential for regional variations in response and safety, influenced by genetic, cultural, and healthcare system factors. This consideration is often overlooked in global guidelines but may be critical for effective implementation in diverse populations.
Policy, Research, and Future Directions
Policy makers and research funders should prioritize controlled trials that address both acute and maintenance efficacy, with attention to diverse patient populations and real-world settings. The review's stepwise, evidence-labeled approach to clinical management offers a practical template, but further refinement will depend on the accumulation of robust, regionally relevant data.
As regulatory agencies and health systems evaluate the integration of ketamine and esketamine into TRD care pathways, ongoing surveillance of safety, misuse, and long-term outcomes will be essential. The coming years are likely to see increased demand for comparative effectiveness research, especially as new rapid-acting antidepressants enter the field.
Reviewed by Dr. Alexei Morozov, MD, PhD, on 2026-11-25. This article synthesizes first-party sources, including the original narrative review (OpenAlex W7237345430), FDA and EMA trial registries, and published clinical trial results.
Get tomorrow's briefing in your inbox
Policy, research, and regulatory signal — delivered on our publish cadence.